Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03759522 (ClinicalTrials.gov)	February 3, 2019	6/11/2018	Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.	Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.	Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy	Drug: DPA -714 PET/MRI	University of Alabama at Birmingham	NULL	Recruiting	18 Years	65 Years	All	120	Phase 1	United States
2	NCT03691077 (ClinicalTrials.gov)	November 11, 2018	28/9/2018	Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714	A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714	Multiple Sclerosis;Relapse;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab	Assistance Publique - Hôpitaux de Paris	Roche Pharma AG;Institut du Cerveau et de la Moelle épinière	Recruiting	18 Years	60 Years	All	51	Phase 3	France
3	EUCTR2017-004158-40-FR (EUCTR)	11/09/2018	04/07/2018	NA	A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 - INN-MS	Patients with Relapsing MS or primary progressive MS MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrevus INN or Proposed INN: ocrelizumab Other descriptive name: ocrelizumab	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	71	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France
4	NCT02305264 (ClinicalTrials.gov)	March 19, 2012	25/1/2013	Imaging of Intracerebral Inflammation in MS	Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive	Drug: 18F-DPA-714 and 18F-FDG	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	65 Years	All	61	N/A	France